Covaxin was a 77.8% effective against Covid, According to Lancet study

Covaxin, using traditional inactivated viral technology, “induced a strong antibody response” two weeks after two doses, according to a statement from The Lancet.

Covaxin, a vaccine developed by the government medical research agency and Bharat Biotech International Ltd.

Using traditional inactivated viral technology, “induced a strong antibody response” two weeks after two doses, according to a statement from The Lancet. During a randomized study of 24,419 participants aged 18 to 97 years in India between November 2020 and May 2021. No vaccination-related painful deaths or adverse events were reported, the medical journal said.

The interim study, funded by Bharat Biotech and the Indian Council of Medical Research. And written in part by representatives from both boards. Is in line with the company’s previous reports on efficacy and safety and could help end the controversy. Over the initial resolution of the injections in January in India.

At this point, the Covaxin was a 77.8% effective has not passed the late-stage test. Which causes wide fluctuations in the first few weeks of the vaccination stimulus. Since then, more than 100 million doses of Covaxin was a 77.8% effective have been use across India. Last week, the World Health Organization added the vaccination to its list of emergency-approved Covid vaccines. 

Nevertheless, in the course of its analysis, the WHO’s independent technical panel investigating the vaccine repeatedly asked the company for additional information. Delaying its inclusion in the organization’s pre-qualification list. And causing disillusionment with Prime Minister Narendra Modi’s government, which is helping residents shot developed

Bharat Biotech president Krishna Ella  earlier attacked those who questioned Covaxin and said at a conference this week that the WHO’s approval had taken a long time to criticize the vaccine, damaging its image.

According to The Lancet, more research is needed to determine the long-term safety and effectiveness of the vaccine and protection. Against serious illness, hospitalization, and death, as well as its ability to ward off deltas and other anxiety disorders.